key: cord-0746065-ccqq5734
authors: Gu, Chunyin; Cao, Xiaodan; Wang, Zongda; Hu, Xue; Yao, Yanfeng; Zhou, Yiwu; Liu, Peipei; Liu, Xiaowu; Gao, Ge; Hu, Xiao; Zhang, Yecheng; Chen, Zhen; Gao, Li; Peng, Yun; Jia, Fangfang; Shan, Chao; Yu, Li; Liu, Kunpeng; Li, Nan; Guo, Weiwei; Jiang, Guoping; Min, Juan; Zhang, Jianjian; Yang, Lu; Shi, Meng; Hou, Tianquan; Li, Yanan; Liang, Weichen; Lu, Guoqiao; Yang, Congyi; Wang, Yuting; Xia, Kaiwen; Xiao, Zheng; Xue, Jianhua; Huang, Xueyi; Chen, Xin; Ma, Haixia; Song, Donglin; Pan, Zhongzong; Wang, Xueping; Guo, Haibing; Liang, Hong; Yuan, Zhiming; Guan, Wuxiang; Deng, Su-Jun
title: A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
date: 2021-02-08
journal: bioRxiv
DOI: 10.1101/2021.02.07.429299
sha: 38be32b65618c66a2e3d41db5be9cda55a01b324
doc_id: 746065
cord_uid: ccqq5734

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.

Coronavirus disease-2019 (COVID- 19) , which is caused by the novel severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2), was first reported at the end of 2019 and has spread worldwide as a severe pandemic (1) . As of February 6, 2021, the World Health Organization (https://www.who.int) has received reports of 104,956,439 confirmed cases including 2,290,488 deaths. Of much more public health concern, numerous SARS-CoV-2 mutants continue to emerge, some of which are reported to have enhanced transmissibility or reduced protective effect by vaccines (2) . receptor on the host cell via the viral receptor-binding domain (RBD) (9) , antibodies that target the RBD are hypothesized to have potent neutralizing activity. SARS-CoV-2 RBD neutralizing antibodies (nAbs) have been isolated from B cells of convalescent patients via single-cell sequencing (10) (11) (12) (13) . However, despite the ability of single-cell sequencing to quickly identify thousands of antigen-binding sequences, tremendous effort is required to produce and profile hundreds or even thousands of recombinant antibodies to obtain nAbs with the desired properties (10) (11) (12) (13) . By contrast, we applied a phage-to-yeast (PtY) platform (14) that combines the advantages of phage display (15, 16) and yeast display (17) to precisely and efficiently identify the desired nAbs from naïve human B cell antibody libraries.

Accordingly, in this study, we report the rapid identification of two potent nAbs against SARS-CoV-2 from our naïve phage-displayed human B cell scFv libraries using a PtY platform. The most potent antibody, JMB2002 (Ab2001.08 N297A), not only showed potent in vitro blocking activity against a broad-spectrum of SARS-CoV-2 variants including the B.1.351 lineage but also potent therapeutic efficacy and complete prophylactic protection against SARS-CoV-2 in a rhesus macaque infection model.

The PtY platform was used to quickly identify potential clones with neutralizing activity against SARS-CoV-2 ( Fig. 1) . First, we screened binders with biotinylated SARS-CoV-2 RBD protein in solution using an in-house naïve phage displayed human B cell scFv library (library size: 2.8 × 10 10 with more than 10-fold coverage to maintain diversity. Specifically, we added hACE2 to a mixture of the yeast display library and the SARS-CoV-2 RBD protein to select clones with potential hACE2-neutralizing activity in solution. After sorting by FACS and sequencing, 117 potential neutralizing clones with unique sequences were identified, and the sequences of these clones were analyzed to avoid those with potential post-translational modifications, which may affect antibody function and stability.

Thirty-four clones from the naïve phage display library were selected for further characterization.

To confirm the specificity of these clones, their ability to bind to the SARS-CoV-2 RBD and to two nonrelated control proteins and their ability to block the binding of the SARS-CoV-2 RBD to hACE2 were tested. Ten clones from the naïve phage display library were identified, and the corresponding mAbs were produced in mammalian cells.

We next used biolayer interferometry (BLI) to determine the affinity of selected and purified mAbs toward the SARS-CoV-2 RBD. As shown in Table 1 , five of the ten antibodies from the naïve phage display library bound to the SARS-CoV-2 RBD with high affinity indicating that the PtY platform successfully identified high-affinity SARS-CoV-2 RBD-binding mAbs.

To evaluate the neutralization ability of the antibodies with specific and strong SARS-CoV-2 RBD-binding activity, we used enzyme-linked immunosorbent assay (ELISA) to test their ability to block SARS-CoV-2 RBD-hACE2 binding. Among the antibodies tested, Ab2001.08 and Ab2001.10 most potently blocked the binding of the SARS-CoV-2 RBD to hACE2 ( Fig. 2A) . Moreover, to determine whether these lead mAbs recognize the same or different RBD epitopes, an epitope binning experiment using BLI was performed, which demonstrated that Ab2001.08 and Ab2001.10 were grouped in different epitope bins (Fig. 2B) . These results showed that the PtY platform precisely identified potent antibodies that blocked RBD binding to hACE2.

To measure the SARS-CoV-2-neutralizing capability of those antibodies, a live SARS-CoV-2 assay was performed by measuring the viral load 24 h after virus infection by quantitative real-time reverse transcription-PCR (qRT-PCR). Compared to an irrelevant IgG control, Ab2001.08, Ab2001.09, Ab2001.10, and Ab2001.08+Ab2001.10 resulted in a greater than 2 log reduction in the viral load at 24 h after infection (Table 1 ). These results indicated that these antibodies exhibited live virus-neutralizing activity.

To compare the potency of Ab2001.08 and Ab2001.10, which showed the most promising activity in inhibiting virus replication, we performed a plaque reduction neutralization tests (PRNTs) using SARS-CoV-2. Ab2001.08 and Ab2001.10 showed PRNT50 values of 12 and 62 ng/ml, respectively (Fig. 2C ).

To select a candidate with the lowest risks for manufacture, physicochemical properties were evaluated. Ab2001.08 displayed desired CMC manufacturability (Table   S1 ) (18) and higher virus neutralization potency than Ab2001.10. Therefore, we selected Ab2001.08 as the lead antibody for further development. Immunogenicity is also critical in the process of therapeutic antibody development (19, 20) . Repeated dosing of a therapeutic protein can lead to B-cell activation, which is triggered by T cell-recognition of peptide epitopes displayed on major histocompatibility complex class II (MHCII) proteins on the surface of mature antigen-presenting cells, resulting in the production of anti-drug antibodies (ADAs). ADAs can influence drug clearance and/or therapeutic efficacy. To predict potential immunogenicity risk, in silico analysis of antibody variable region gene sequences was performed using an in-house developed algorithm to assess potential T-cell epitopes. The algorithm provides value as a ranking tool; that is, a lower value indicates lower immunogenicity. By this algorithm, Ab2001.08 was predicted to show low immunogenicity compared to that of some marketed therapeutic antibodies (Table S2A ). Additionally, JMB2002 has a comparable somatic hypermutation rate (SHM) ( Table S2B ) compared to nAbs isolated from convalescent COVID-19 patients, suggesting low potential immunogenicity of this antibody.

Overall, our data showed that potent nAbs with diverse epitopes and good developability could be identified by the PtY platform ( Fig. 1) . Table S3 ). After Fc modification, JMB2002 could still bind to FcRI (CD64), with an affinity approximately 9-fold lower than that of Ab2001.08, whereas its binding ability to FcRIIA (R/H167) and FcRIIIA (F/V176) was markedly reduced ( Fig. 3A and Table   S3 ).

To evaluate ADE activity, we infected to a double-mutant RBD (N354D/D364Y) and a mutant RBD (L452R) was decreased approximately 3.5-and 65-fold, respectively, compared with its binding to a prototype RBD ( Fig. 4A and Table S4A ). JMB2002 also bound to SARS-CoV-2 S1 (D614G), a currently widespread strain with increased infectivity, with a KD of 11.9 nM. Moreover, the binding affinity was similar to that for SARS-CoV-2 S1 (Fig. 4B and Table S4B ).

We also assessed the binding activity of JMB2002 to recently emerged SARS-CoV-2 mutants from UK and South Africa. Encouragingly, JMB2002 showed 1.9-and 6.8fold higher affinity to the UK and South African mutants when compared to S1 prototype, respectively ( Fig. 4B and Table S4B ). These results demonstrated that JMB2002 could bind to a broad range of SARS-CoV-2 RBD variants with high affinity, indicating that this mAb has broad-spectrum activity against SARS-CoV-2 strains.

We next performed ELISA to test the blocking activity of JMB2002. JMB2002 Table S4A ).

In addition, the blocking effect of JMB2002 on the N354D/D364Y and W436R RBDs was approximately 1.7-and 4.3-fold, respectively, stronger than that on the RBD prototype ( Fig. 4C and Table S4A ). Although hACE2-Fc prevented the SARS-CoV-2 RBD from binding to hACE2, it was approximately 67-fold less potent than JMB2002 ( to that of S1 prototype ( Fig. 4D and Table S4B ). Interestingly, the blocking activity of JMB2002 toward the UK mutant was decreased 17-fold ( Fig. 4D and Table S4B) although the binding activity increased by 1.9-fold ( Fig. 4B and Table S4B) , as compared to S1 prototype. Moreover, the potency of JMB2002 was 12-fold and 3.4fold higher than that of hACE2-Fc against the South African and UK mutants, respectively (Fig. S1 ). The activity of antibody CB6, which was included as a comparator, was impaired against the UK mutant and markedly abolished against South African mutant (Fig. S1 ).

To determine the neutralizing activity of JMB2002, we performed a pseudovirus neutralization assay in which the entry of pseudovirus into the hACE2-expressing cell line was correlated with an increased luciferase signal in the cells. JMB2002 and Ab2001.08 showed potent neutralization ability, with half-maximal inhibitory concentration (IC50) values of 4.25 and 5.09 ng/ml, respectively, against SARS-CoV-2 pseudovirus (Fig. 4E ). Additionally, Fc modification of Ab2001.08 had no effect on its neutralizing activity.

Based on the potent neutralizing activity and desired developability described above (Table S1) In the therapeutic group, the viral RNA of one animal was reduced by approximately 3 logs compared with that of the control animal at 5 dpi (Fig. 5B) .

Notably, the viral load of the other animal in the therapeutic group was reduced to less than the detection limit at 3 dpi (Fig. 5B) . These results suggested that JMB2002 can provide complete protection and potent therapeutic efficacy in vivo. Because COVID-19 is predominantly a lung infection, we also examined the ability of JMB2002 to protect against lung damage from SARS-CoV-2 infection. All animals were sacrificed and necropsied at 7 dpi. Based on evaluation of pneumonia severity, the control animal was diagnosed with viral pneumonia with extensive pulmonary fibrosis, exhibiting pathology including thickened alveolar septa, fibroblast proliferation and fibrosis, and intensive monocyte and lymphocyte infiltration (Fig. 5C ). In some alveolar cavities, cellulose exudation was observed, with hyaline membrane formation and pulmonary hemorrhage. By contrast, animals treated with JMB2002 before or after infection displayed very limited pathological lung damage characterized by an overall intact alveolar structure, reduced edema and the absence of hyaline membrane formation, with less fibrosis and less leukocyte infiltration than the control animal (Fig.   5C ). In summary, JMB2002 reduced infection-related lung damage in both the prophylactic and therapeutic animal groups, suggesting that JMB2002 is an effective therapeutic.

To rapidly develop therapeutic antibodies in response to SARS-CoV-2 infection, we applied a PtY platform to identify a potent nAb JMB2002 in a precise and efficient manner, suggesting that the PtY platform can meet the needs of an immediate response to a global pandemic by accelerating research and development of nAbs. PtY, a unique human mAb discovery platform, offers the following 5 advantages: 1) the ability to identify lead SARS-CoV-2 nAbs from a naïve scFv library without using B cells from COVID-19 convalescent patients; 2) the ability to isolate rare nAbs from the libraries identified antibody JMB2002 not only bound to the SARS-CoV-2 S1 prototype and SARS-CoV-2 S1 (D614G) mutant with similar affinity but also exhibited improved potency in blocking the binding of SARS-CoV-2 S1 (D614G) to hACE2. Furthermore, three mutations, i.e., L452R, A475V, and V483A, have been shown to exhibit marked resistance to some antibodies (29). Specifically, the neutralizing activity of antibodies B38, P2C-1F11, CB6, and 247 against A475V was decreased approximately 100-fold.

Moreover, RBD L452R also reduced the sensitivity to antibodies X593 and P2B-2F6 and V483A to antibody X593 by approximately 100-fold (29). In contrast, JMB2002 lower when compared to S1 prototype. Moreover, the potency of JMB2002 was 12-fold and 3.4-fold higher than that of hACE2-Fc against the South African and UK mutants, respectively, further indicating effective blocking of these two mutants by JMB2002.

Collectively, these findings suggested the possibility of hACE2 receptor mimicry by JMB2002, indicating the potential ability of JMB2002 to exhibit broad-spectrum blocking activity against RBD mutants, an intuitive conclusion, since JMB2002 was identified by its ability to compete for hACE2 binding in solution. We then developed a novel competitive FACS approach to rapidly identify potential blocking antibodies (Fig. 1) . Specifically, the library were incubated with SARS-CoV-2 RBD containing a mouse Fc tag (Sino Biological, 40592-V05H), and biotinylated hACE2 (Kactus, ACE-HM401) was then added. Next, the libraries were 

We conducted epitope binning of mAbs with an Octet Red96 (ForteBio, Sartorius) using an in-tandem format, in which mAbs competed against one another were in a pairwise combinatorial manner for binding to the SARS-CoV-2 RBD protein. Assays were performed at 30°C with continuous agitation at 1000 rpm. After obtaining an initial baseline in kinetics buffer, 1 μg/ml biotinylated SARS-CoV-2 RBD (Kactus, COV-VM4BD) was captured onto a SA biosensor (ForteBio, 18-5020) for 65 s. To saturate the binding sites for the first mAb on the SARS-CoV-2 RBD antigen, we exposed all sensors for 3 min to the first mAb (15 μg/ml) after immersion in kinetics 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States

Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results

Antibody-mediated protection against Ebola virus

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker

Making antibodies by phage display technology

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

Yeast surface display for screening combinatorial polypeptide libraries

Developability assessment during the selection of novel therapeutic antibodies

Improved methods for predicting peptide binding affinity to MHC class II molecules

Removing T-cell epitopes with computational protein design

Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Cross-reacting antibodies enhance dengue virus infection in humans

CoV-2 lineage in the UK defined by a novel set of spike mutations

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

An improved yeast transformation method for the generation of very large human antibody libraries

We thank all colleagues from the National Biosafety Laboratory (Wuhan), Chinese Academy of Sciences, for their support during the study. We also thank our colleagues from the Center for Instrumental Rectalysis and Metrology, Wuhan Institute of Virology, Chinese Academy of Sciences. We thank Dr. C. Roger MacKenzie for critical reading and editing of our manuscript.

The main data supporting the results in this study are available within the paper and Supplementary Information. Datasets are available from the corresponding authors upon reasonable request.